

Corporate Presentation

Full-Year 2023 Earnings Call

March 15, 2024

Disclaimer

This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates, expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials, the potential therapeutic and clinical benefits of Molecular Partners' product candidates, the selection and development of future programs, and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2024 and its expectation of its current cash runway. These statements may be identified by words such as "guidance", "believe", "expect", "may", "plan", "potential", "will", "would" and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may impact Molecular Partners' financial and business projections and guidance and may cause Molecular Partners' actual results and outcomes to materially differ from its guidance; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners' Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with Securities and Exchange Commission (SEC) on March 14, 2024 and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of Molecular Partners' website at www.molecularpartners.com.

Any forward-looking statements speak only as of the date of this presentation and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.




Agenda & Speakers





The DARPin Modality and Molecular Partners' Strategy



What we invented

- New class of therapeutics: Designed Ankyrin Repeat Proteins (DARPins)
- DARPins to close the gap between small molecules and antibodies
- 7 clinical-stage compounds, >2500 patients treated

How we apply it

- Unique DARPin solutions for a defined medical problems not addressable by antibody designs
- Demonstrate true patient value with early clinical readouts
- Combine our capabilities with world-class partners to deliver innovative therapeutics



2023 Highlights

18

MP0533	 Novel tetra-specific T cell engager for R/R AML and high-risk MDS/AML patients ASH 2023: encouraging initial clinical data with acceptable safety and initial activity Phase 1/2a study with dose-escalation well on track; dosing patients in DR 6 ongoing
Switch-DARPin & cKIT	 Demonstrated proof-of-concept for Switch-DARPin platform at PEGS 2023 1st program, cKIT x CD16a x SWITCH-CD47; targeted conditioning regimen for HSCT in AML & beyond
Radio- DARPin Therapy	 Successful RDT platform optimization to reduce kidney accumulation and increase tumor uptake Collaboration agreement with Orano Med to co-develop RDTs with up to three targets, including DLL3 Novartis collaboration progressing according to plan on two targets
MP0317	 Bi-specific CD40 agonist targeting FAP for tumor-localized immune activation with favorable safety profile confirmed tumor-localized CD40 activation leading to remodeling of TME in patients
Operations	 Strong financial position with CHF ~187 M in cash as of Dec. 31, 2023 Capitalized well into 2026



AML, acute myeloid leukemia; ASH, American Society of Hematology; DLL3, Delta-like ligand 3; DR, dose-regimen; EANM, European Association of Nuclear Medicine; FAP, fibroblast activation protein; MDS, myelodysplastic syndrome; RDT, Radio-DARPin Therapy; R/R, relapsed/refractory; SITC, Society for Immunotherapy of Cancer; TME, tumor microenvironment.

Pipeline

CANDIDATE	RESEARCH	PRE-CLINICAL	PHASE 1	PHASE 2	RIGHTS
MP0317	Advanced Solid Tumors FAP x CD40				MOLECULAR partners
MP0533	R/R AML and AML/MDS: CD33 x CD123 x CD70 x C	D3			MOLECULAR partners
Switch-DARPin	AML/HSCT cKIT x CD16a x CD47				MOLECULAR partners
	Undisclosed				MOLECULAR partners
Radio-DARPin Therapy	DLL3	Co-development*			Molecular partners
merapy	Solid Tumors	In-house programs			MOLECULAR partners
	Solid Tumors	2 partnered programs			U NOVARTIS
Virology					MOLECULAR partners





Financial Overview

Key Figures FY2023

(CHF million, except per share and FTE data)	FY 2023	FY 2022	change
Revenues	7.0	189.6	(182.6)
Total operating expenses ¹	(68.1)	(73.0)	4.9
Operating result	(61.1)	116.6	(177.7)
Net financial result	(0.9)	1.2	(2.1)
Net result	(62.0)	117.8	(179.8)
Basic net result per share (in CHF)	(1.89)	3.63	(5.52)
Net cash from / (used in) operations	(59.0)	118.6	(177.6)
Cash balance (incl. s.t. deposits) as of Dec 31 ²	186.9	249.1	(62.2)
Number of FTE's as of Dec 31	167.5	175.3	(7.8)



¹ Thereof non-cash costs of CHF 8.1 m in FY2023 and CHF 8.6 m in FY2022 ² Including CHF 119.6m short-term time deposits (2022: 161.2m) Note: Rounding differences may occur

Financial Guidance* for 2024

• Total expenses of CHF 70-80 million,

of which around CHF 8 million non-cash effective costs

 ~CHF 187 million cash & cash equivalents (incl. short-term time deposits) ensure comfortable funding well into 2026 (excl. any potential payments from R&D partnerships)

* Guidance subject to progress and changes of pipeline






MP0533

Tetra-specific T cell Engager for AML

MP0533: Avidity-Driven Selectivity for Cancer Cells in AML

PROBLEM: AML-associated antigens are also expressed on healthy cells



AML remains a deadly disease and persistence of LSCs drives relapse


AML cell population is heterogeneous:

- Individual AML blasts and LSCs lack a clean target
- AML cells can be differentiated from healthy cells (e.g. HSCs) by their co-expression of specific targets (e.g. CD33, CD123, CD70)



MP0533: Avidity-Driven Selectivity for Cancer Cells in AML

SOLUTION: MP0533 induces T cell-mediated killing of cells co-expressing TAAs




MP0533 is designed to induce **T cell-mediated killing preferentially when 2 or 3 target antigens** (CD33, CD123, CD70) **are co-expressed**


MP0533 is hypothesized to preserve healthy cells, hence **opening a therapeutic window**

MP0533 has the potential to kill all AML cells (blasts and LSCs) despite heterogeneity, ensuring **long-term disease control**



MP0533 Induces Specific Killing of AML Cells Expressing Two or Three TAAs






Bianchi et al, manuscript tentatively accepted in Feb 2024 for publication



MP0533 Phase 1 Dose-escalation Trial in R/R AML patients



Study currently dosing patients in DR 6, plans to present data in H1 2024



AML, acute myeloid leukemia; D, treatment cycle day; DLT, dose-limiting toxicity; DR, dose regimen; MDS, myelodysplastic syndrome; n, number of patients; PD, pharmacodynamic; PK, pharmacokinetics; POC, proof of concept; RP2D-R, recommended phase 2 DR; R/R, relapsed/refractory.

MP0533 - Patient Characteristics and Safety Profile


PATIENT CHARACTERISTICS	DR COHORTS 1–4 (n=11)	MP0533-RELATED TEAEs (n=43 reported)			
Sex, n (%) Female / male	5 (45) / 6 (55)	Angina unstable			
		CRS Diarrhea	3 1		
Age Mean / Median (range)	66 / 75 (26–81)	DIC	11		
		Erythema multiforme	1		
ECOG PS, n (%) 0 / 1 / 2	4 (36) / 5 (46) / 2 (18)	Headache	1		
		Hepatic cytolysis	1		
Hematologic malignancy, n (%)	0 (00) (0 (40)	IRR		16	6
AML / MDS/AML	9 (82) / 2 (18)	Lymphocyte count decreased	1		
ELN risk category, n (%)		Lymphopenia	2		
Intermediate / adverse	1 (9) / 10 (91)*	Nausea	2		
No. of prior systemic treatment lines, n (%)		Neutropenic colitis	2		
1/2/3	4 (36) / 5 (46) / 2 (18)	Troponin I increased	1	Grade 1 = Mild	
		Ventricular arrythmia (extrasystoles)	1	Grade 2 = Moderate	
*TP53 mutated: 3 (27%)		Weight increased	1	Grade 3 = Severe	

Acceptable safety profile for MP0533 reported for DR 1–4 (11 patients):

- Overall, AE profile consistent with AML and elderly/heavily pretreated patients with many comorbidities
- IRR and CRS are the most frequent MP0533-related TEAEs (Grade 1-2)
- No DLTs in any of the MP0533 DRs to date




MP0533 Treatment and Clinical Response





MP0533 Phase 1 Dose-escalation Trial in R/R AML patients



Study currently dosing patients in DR 6, plans to present data in H1 2024



AML, acute myeloid leukemia; D, treatment cycle day; DLT, dose-limiting toxicity; DR, dose regimen; MDS, myelodysplastic syndrome; n, number of patients; PD, pharmacodynamic; PK, pharmacokinetics; POC, proof of concept; RP2D-R, recommended phase 2 DR; R/R, relapsed/refractory.

17



Switch-DARPin Platform & first program for HSCT in AML

Targeted and conditional activation of immune cells

Next-Generation Conditioning for HSCT in AML and Beyond


HSCT is potentially curative for AML, however:

Conditioning regimens followed by HSCT do not always kill all AML cells^{1,2}

→ Many patients relapse post HSCT, especially AML patients with poor cytogenetic risk profile

High-intensity conditioning regimen bears high toxicity^{1,2}

→ Many patients receive reduced intensity conditioning with higher risk of relapse or do not qualify for HSCT



Opportunity for next-generation conditioning regimen

- Induce deep molecular remission to kill all AML clones, including in patients with poor cytogenetic risk profile
- Limit toxicity to allow access to HSCT for more AML patients, including elderly or frail patients
- Beyond AML: broaden applicability of HSCT for other diseases (e.g., genetic diseases) by improving safety of conditioning regimen



Next-Generation Conditioning for HSCT in AML

Target cKIT to eliminate HSCs/LSCs


- cKIT is critical for stem cell maintenance and renewal^{1, 2}
- Simple antagonists (mAbs) to cKIT are not potent enough

Engage NK cells and macrophages (M Φ) via CD16a to kill HSCs/LSCs

- · Effective and safe approach
- NK and MΦ activity is limited by CD47 expression on HSC/LSCs³

Conditionally block CD47 on LSCs/HSCs to boost NK cell and MΦ killing activity

- CD47 is widely expressed as "do-not-eat-me signal" and prevents killing of cells, including HSCs/LSCs^{1,3}
- Swich MoA allows conditional local blocking of CD47 on HSCs/LSCs





Higher safety Expected better biodistribution Allows use of Fc-engaging modalities

α-CD47

cKIT x CD16a x CD47 Switch-DARPin

Our solution for a safe conditioning regimen and long-term disease control

cKIT (CD117)

α-HSA

HSC marker essential for HSC maintenance and renewal

• **Challenge:** optimal HSC depletion requires both cKIT blocking AND potent immune cell mediated killing

 α -CD16a

cKIT-CD16a-CD47 Switch-DARPin proposed to demonstrate full activity

CD47 innate checkpoint blockade

Switch-DARPin

- Block "do-not-eat-me" signal = enhances phagocytosis
- High expression on HSC = target for ADCC and ADCP

21

Prevents peripheral CD47 blockade

ADCC and ADCP induction


Innate immune cell engager

CD16a effector function

- No impact of inhibitory Fc
- Reduced CRS (compared to TCE)




Switch-DARPin POC - CD47 is Blocked Only on cKIT Positive Cells





c-KIT x CD16a x CD47 Switch-DARPin shows superior ADCP activity compared to a combo of an Fc-active (IgG1) anti-cKIT Ab + Magrolimab

ADCP assay M0-like Macrophages + Kasumi-1 AML cell line




*Fc-active version of JSP-191, reproduced by MP






Radio-DARPin Therapy

Platform & Pipeline




Ideal Properties of Radiotherapy Product Candidate






LMW Molecules as Ideal Vectors but Limited Target Space



<u>MOLECULAR</u>

* Source: Guggenheim Securities Report 2023 ** e.g. FAP, CAIX, FOLR1, NTSR1, Eph2A, GPC3, MC2R, GRPR, ITGB6 LMW, low molecular weight; NET, neuroendocrine tumor

The Engineering Strategy for RDT Candidates





T: Tumor

K: Kidney B: Blood

Surface Engineering to Reduce Kidney Accumulation Enabled by the robust architecture of DARPin scaffold











Lizak C, et al.; SNMMI 2023 oral presentation




Evolution of Surface Engineering for RDT Engine





AT PROGRAM START: Iterative rounds of DARPin surface engineering and *in-vivo* testing needed to reach low kidney accumulation




TODAY: A single round of DARPin surface engineering to reach low kidney values for many DARPin binders



* Kidney value of best surface variant per engineering round displayed in graph: 4h timepoint in wt or tumor-bearing mice; DARPins conjugated to different chelators and labelled with different radioisotopes

Systemic Half-life Extension (HLE) Increases Tumor Uptake

Establishing a HLE toolbox with different "strengths & properties" to tailor to specific needs



partners

Her2 and DLL3 DARPins conjugated to different chelators, labelled with different radioisotopes; and tested in different mouse tumor models; αSA: HLE moieties binging to serum albumin


RDT Engine & Pipeline

Leverage Radio DARPin Engine & build pipeline

• Tailor candidate properties to specific target needs and radioisotope

Partnering model to join forces with leaders in the field

- Cross-pollination of R&D knowledge
- Access radioisotopes & supply chain







Outlook

2024 Outlook and Upcoming Milestones

MP0533	 Interim update from Phase 1/2a trial to be presented in H1 2024 Expansion of enrolment to higher dose cohorts (protocol amendment ongoing) planned in H2 Plans for future clinical development strategy, incl. preparation of potential US IND application
Switch-DARPin & cKIT	 Initial preclinical data presentation on cKIT x CD16a x CD47 program in H1 2024 Preclinical proof-of-concept data from NHP study in H2 2024, with strong translational value Leverage Switch-DARPin platform for next-generation immune cell engagers
Radio- DARPin Therapy	 DLL3 lead RDT candidate selection in H1 2024 to advance into IND-enabling studies with FIH in 2025 Nominate additional RDT targets and pipeline candidates Continue to broaden clinical and supply collaborations with radionuclide companies
MP0317	 Full data from the Phase 1 dose escalation in H1 2024 Partnering for clinical development in combination settings

CHF ~187 million cash* (incl. short-term time deposits) ensures funding well into 2026



*As of December 31, 2023. AML, acute myeloid leukemia; IND, investigational new drug; NHP, non-human primate; R/R, relapsed/refractory; ASH, American Society of Hematology.



Thank You




Back-up

2023 Financials



Revenues Development

in CHF million




- CHF 7.0 million revenue in 2023, Novartis
 RLT collaboration
- CHF 190 million revenues in 2022, largely driven by Novartis collaboration
- Revenues in prior years mostly related to Amgen collaboration

Note: Rounding differences may occur



Operating Expenses

in CHF million



Highlights 2023

- Expense development in line with expectations
- Expenses include CHF 8.1 million non-cash effective costs
- Main drivers of changes to prior year
 - Year on year reduction in costs related to US listing of CHF 2.7 million
 - Personnel cost, reflecting effective FTE numbers
 - Lower R&D cost reflect reduction of expenses associated with legacy programs, but also increase in core research and RDT

Note: Rounding differences may occur



Balance Sheet (as of December 31, 2023)

CHF million

198.4	198.4
Other assets 11.5	Other Liabilities 17.7 Contract liabilities 4.3
Cash balance (incl. short-term deposits) 186.9	Shareholders' equity 176.4

Highlights

- CHF 186.9 million cash balance (incl. short-term deposits)
- Contract liability of CHF 4.3 million to be recognized as revenue in 2024
- Strong equity base with CHF 176.4 million
- Debt free



Balance Sheet (as of December 31, 2023)

(CHF million)	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Non-current assets	5.9	7.5	8.5	9.7	5.0
Other current assets ¹	5.6	5.6	31.4	4.1	4.8
Cash balance	186.9 ¹	249.1	132.8	173.7	95.1
Shareholders' equity	176.4	235.2	107.3	107.2	54.1
Non-current liabilities	7.5	9.8	18.5	22.7	22.2
Current liabilities	14.4	17.3	46.9	57.7	28.6

¹ Includes CHF 119.6 million of short-term time deposits Note: Rounding differences may occur



Income Statement

(CHF million)	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenues / other income	7.0	189.6	9.8	9.3	20.4
R&D expenses	(48.8)	(50.7)	(55.7)	(56.1)	(43.5)
SG&A expenses	(19.4)	(22.3)	(17.5)	(11.6)	(13.6)
Operating result	(61.1)	116.6	(63.4)	(58.3)	(36.7)
Net financial result	(0.9)	1.2	(0.4)	(4.4)	0.4
Net result	(62.0)	117.8	(63.8)	(62.8)	(36.3)

Note: Rounding differences may occur



Cash Flow Statement

(CHF million)	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net cash from / (used in) operations	(59.0)	118.6	(91.0) ¹	(29.0)	(1.2)
Net cash from / (used in) investing ²	44.6	(101.1)	(22.2)	(21.7)	(19.8)
Net cash from / (used in) financing	(1.2)	(1.6)	50.6 ³	113.2 ³	(0.2)
Exchange gain / (loss) on cash	(5.1)	0.3	0.7	(4.5)	(2.0)
Net cash increase / (decrease)	(20.6)	16.1	(61.9)	58.0	(23.2)
Cash balance at year end	186.9	249.1	132.8	173.7	95.1

¹ Includes CHF 20 million paid to Novartis

² Includes movements in short-term time deposits

³ For 2021 this includes the funds received from the listing in the US; for 2020 this includes two capital raises

Note: Rounding differences may occur






MP0317

Tumor-localized Immunotherapy

MP0317: Unlocking CD40 Activity Through Local Activation

PROBLEM: Toxicity of CD40 Agonists has so far limited their potential



CD40 agonists can activate **B cells, DCs and MΦ** to enhance the efficacy of anticancer treatment, especially in "cold tumors"


Systemic activation of CD40 via mAbs has been hampered by **significant toxicities**

 Limiting potential CD40 agonists to reach therapeutically active doses



MP0317: Unlocking CD40 Activity Through Local Activation

SOLUTION: MP0317 – FAP-dependent tumor-localized CD40 activation



FAP is a validated tumor target

- Overexpressed in \geq 28 different cancer types
- Expression not downregulated during disease progression


MP0317 designed to

- Bind tumor-localized FAP and induce CD40mediated activation of immune cells in the tumor
- Overcome systemic toxicity, allowing a wider therapeutic dosing range



MP0317 Phase 1 Study Design and Status

First-in-human, multicenter, dose-escalation study in adults with advanced solid tumors



Primary Study Objectives

- MP0317 safety and tolerability
- Recommended dose for expansion
 and combination

Updated Data Presented at SITC 2023¹


- Enrollment completed in doseescalation part; 46 patients treated
- Favorable safety profile up to highest planned dose (10 mg/kg); one DLT
- Favorable exposure profile across dosing schemes (Q1W, Q3W)
- Clinical evidence of tumor-localized CD40 pathway and immune cell activation, leading to TME remodeling

45




¹Gomez-Rocca et al. SITC 2023 poster presentation. The study is registered at ClinicalTrials.gov (NCT05098405). PD, pharmacodynamic; Q1W, weekly dosing; Q3W, every-3-weeks dosing; DERC, dose escalation review committee; DLT, dose-limiting toxicity; TME, tumor microenvironment.

Exposure to MP0317 is maintained in patients across dosing schemes and cohorts



MP0317 Co-localizes with FAP and CD40 in Tumors – Concomitant Increase in Intra-tumoral DCs Observed

PRIOR TO TREATMENT



CYCLE 2 DAY 8

Minimal DC presence in FAP-positive tumor area

Mol par

MOLECULAR Gomez-Roca et al, SITC 2023 poster presentation

High DC infiltration in FAP-positive tumor area in MP0317 presence


Tumor biopsy of a patient with GIST in Cohort 5b (Q1W); biopsy location: peritoneum. DC, dendritic cell; FAP, fibroblast activation protein; GIST, gastrointestinal stromal tumor.



Back-up

Switch-DARPin

Logic-gated Switch-DARPins Swiss knives for enhanced immune engagers



HSA DARPin(s) For Half life extension

✓ CLINICALLY VALIDATED

Switch-DARPin

to prevent systemic immune-cell activation

- Allows safe use of potent immune-cell effectors
- Better biodistribution (no immune target-mediated sink)


hypothetical sketch






Back-up

Radio-DARPin



Rationale for Developing ²¹²Pb-based RDTs Collaboration with Orano Med

- ²¹²Pb has key advantages as radioisotope ^[1]:
 - Efficacy short decay half-life is leading to high energy deposition on tumor in short time frame and might be beneficial for early combination with immunotherapy
 - Safety clean decay chain ²¹²Pb is an alpha precursor with low risk for long-lived free daughter radionuclides
 - 3) Less problematic waste management due to short half-life
- RadioLigand Therapy commands excellent logistics with all isotopes
- OranoMed as strong collaboration partner
 - Leading the field of ²¹²Pb for Targeted Radiotherapy
 - "Endless" radioactive starting material as basis for supply
 - Collaboration between MP / OM established over >12 months
 - Strong platform & product progress
 - Trust, Complementary and deep expertise



Adapted from Li et al., Current Medicinal Chemistry, 2020

